Drugs /

refametinib

Back to Drugs List
Associated Genetic Biomarkers

Overview

Generic Name(s):
refametinib
NCI Definition [1]:
An orally bioavailable selective MEK inhibitor with potential antineoplastic activity. Refametinib specifically inhibits mitogen-activated protein kinase kinase 1 (MAP2K1 or MAPK/ERK kinase 1), resulting in inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK, a dual specificity threonine/tyrosine kinase, is a key component of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth; constitutive activation of this pathway has been implicated in many cancers.

Clinical Trials

View Clinical Trials for refametinib

Refametinib has been investigated in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial investigating refametinib, 1 is phase 1 (0 open).

Breast carcinoma, colorectal carcinoma, and malignant solid tumor are the most common diseases being investigated in refametinib clinical trials [2].

Drug Details

Synonyms [2]:
rdea119, bay86-9766, mek inhibitor rdea119, mek inhibitor rdea119, rdea-119, rdea 119, refametinib, bay 869766, bay-869766, bay869766, rafametinib, bay 86-9766
Drug Categories [2]:
MEK inhibitors, Serine/threonine kinase inhibitors, Tyrosine kinase inhibitors
Drug Target(s) [2]:
MAP2K1, MAP2K2
NCIT ID [1]:
C74059

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.